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1. Introduction
Autism is a behaviourally defined developmental disorder characterised by impairments in
social communication, restricted interests and repetitive behaviours [1]. Abnormalities in these
three developmental areas tend to cluster together in affected individuals. In DSM-IV, Autism
is part of a larger continuum of disorders collectively called Pervasive Developmental Disor‐
ders. Autism spectrum disorders (ASD) refer to Autism, Pervasive developmental disorder,
not otherwise specified, and Asperger syndrome. All individuals with ASDs have qualitative
abnormalities of social development in combination with disorders of communication and/or
stereotyped repetitive interests and behaviors. The social skills that develop naturally in typ‐
ically-developing children do not do so in children with ASD. In addition, there are several
behaviors and co-morbid symptoms that relate to each of the three classical impairments. Re‐
cent studies have reported rates of co-occurring intellectual disability in the range of 25-50%.
Neither developmental delay nor cognitive impairment are required for an ASD diagnosis.
Fombonne and colleagues recently estimated the prevalence of strictly–defined autism at ap‐
proximately 15-20 per 10,000 people [2]. When the definition of autism is relaxed to include
Autism Spectrum Disorders, the prevalence estimated expands to approximately 60 in in
10,000 children [2, 3].
Little is known of the biological basis of ASD and the future development of rational knowl‐
edge based treatments will depend on a comprehensive understanding of innate biological
predisposition and its interaction with environmental factors. The identification and charac‐
terisation of the genetic variation and genes involved in ASD is a route towards this goal. This
chapter outlines the various approaches that have been applied to this task, in the context of
rapidly evolving technology and human genome resources, and summarises the state of
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knowledge at this time, anticipating future developments, and outlining the implications for
clinical management.
2. Autism is a heritable disorder
There is unequivocal evidence to support the role of genetic liability as the basis of familiality
in the aetiology of ASD. In their seminal work, Folstein and Rutter [4] observed that 4 of 11
(36%) pairs of identical twins were concordant for strictly defined autism – whilst none of 10
pairs of fraternal twins were concordant. In a large follow-up study, which included these
original twins, Bailey and colleagues observed a more striking concordance rate in identical
twins (60%) with no concordance in the fraternal twins [5]. This highly cited study underlined
ASD as the most heritable of the neurodevelopmental and psychiatric disorders with herita‐
bility estimates of 91 - 93%. A recent review of over 30 twin studies of ASD [6] noted that the
early twin studies, which relied upon a strict diagnosis of autism, show a median identical and
fraternal concordance of 76% and 0% respectively. The expansion of these and other studies
to include a broader definition of ASD revealed a median concordance rate of 88% and 31%.
In both cases, these data reveal that ASD is underpinned by a strong genetic component. More
recently, Hallmayer and colleagues [7] using more stringent clinical diagnostic tools, such as
the Autism Diagnostic Interview (ADI; [8]) and the Autism Diagnostic Observation Schedule
(ADOS; [9]) in a group of 202 twin pairs from the California Twin Registry, identified similar
concordance rate of ASD as previously attained; with identical twin boys showing a concord‐
ance rate of 77% and fraternal twin boys 31%.
3. Genetic linkage and association
The heritability estimates above calculated from twin studies imply that there is unknown
genetic variation in children with ASD that confers risk. Several models may fit the observed
family and twin data including, at the extremes, a ‘common disorder-common-variant’ model,
with many DNA variants of small effect combining together to create risk; and a multiple rare
variant model where ASD is in reality a large collection of different and individually rare
disorders. The true picture is only slowly emerging, and as with many other common disor‐
ders, common low penetrant and rare higher penetrant DNA variants combine to jointly con‐
tribute to risk. Molecular genetic methods have developed exponentially over the last few
decades with ever increasing knowledge of the structure and function of the human genome.
For disorders with largely unknown aetiology, such as ASD, using human genetic studies to
identify risk genes is a gateway to an understanding of underlying biology. Such studies may
focus on individuals or families each using different but related genetic strategies to track
down risk or causative genetic variation. These methods include genetic linkage, genetic as‐
sociation, and direct examination of structural and copy number variation.
The basis of genetic linkage is the physical co-location of genes or other DNA variation. Such
DNA variation is more likely to be transmitted together (or linked) than those that are further
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apart. Linkage studies take advantage of this non-random assortment of genetic variation. A
linkage study calculates whether a known genetic variant and a disease mutation (represented
by the disease trait) are linked and if so, roughly localises the causative mutation. Following
the successes of using these approaches in the discovery of multiple loci implicate in Mendelian
disorders, researchers were encouraged to apply linkage methodology to more complex traits,
such as ASD where Mendelian principles may apply, at least in a proportion of families. How‐
ever, in ASD, only a few scans have highlighted loci with significant linkage, highlighting loci
including chromosome 7q, 2q and 3q.
In 1998, the International Molecular Genetic Study of Autism Consortium (IMGSAC) [10] re‐
ported modest evidence for linkage. This included significant linkage arising on chromosome
7q32-q34. Supplemented analyses of IMGSAC families provided additional support for link‐
age at 7q22, 16p13, and 2q31 [11, 12]. The long arm of chromosome 7 has received particular
attention with additional support reported for 7q21 [13], 7q22 [14], 7q31 [15, 16], 7q32 [17] and
7q36 [16].
Few individual families exist where ASD segregates in an obvious Mendelian fashion that is
large enough to provide significant evidence for linkage by themselves. Most linkage studies
required the assumption that a significant proportion of the families in the sample might be
linked to a given locus and few were sufficiently large to accommodate even modest locus
heterogeneity. Under a ‘common disorder - common variant’ model, multiply affected families
will occur but linkage methods would be considerably underpowered. The effects of DNA
variation with low penetrance are more easily identified using a genetic association study
design in a sample of cases drawn from a population.
Fine-mapping and candidate gene association studies at implicated regions on 7q have impli‐
cated a number of potential susceptibility genes including RELN, MET, CNTNAP2 and EN2.
Persico and colleagues [18] studied five DNA variants or polymorphisms across the RELN
gene locus, including a GGC repeat variant located close to the RELN gene translation initiator
codon. Located at 7q22, RELN encodes an extracellular matrix protein Reelin, which plays a
pivotal role in the development of laminar structures including cerebral cortex, cerebellum
and hippocampus. Using a genetic association approach, Persico and colleagues identified a
nominally significant association with this 5’-UTR GCC-triplet-repeat polymorphism [18].
This finding was further supported by some studies [19-25] but not others [26-31]. MET, located
at 7q31 received considerable attention following a high-profile association reported by Camp‐
bell and colleagues. The MET gene encodes a protein involved in MET (Mesenchymal epithelial
transition factor) receptor tyrosine kinase signalling which has been implicated in brain growth
and maturation – offering biological plausibility to its candidature. As with other candidate
genes in ASD, the original findings have been supported in some [32], but not other studies
[33] [34]. A similar scenario played out for the EN2 homeobox gene located at 7q36 [35, 36].
Arking and colleagues [37] observed an association at CNTNAP2 in the NIHM/AGRE collec‐
tion. The main association observed was for rs7794745 located in intron 2 of the gene (Discovery
P = 0.00002, Validation P = 0.005). The CNTNAP2 (7q35) gene encodes the contactin-associated
protein-like 2 protein, which is a member of the neurexin family and thought to play a role in
axonal differentiation and guidance. Li and colleagues also found mild support for CNTNAP2
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where they observed a weak association with a haplotype containing the SNP rs7794745 [38].
More recently, a large GWAS of 2705 families identified a strong association for the SNP
rs1718101 in the CNTNAP2 gene with a subset of individuals without intellectual disability
and of European ancestry (P = 7.78 x 10-9) [39].
The Paris Autism Research International Sibpair (PARIS) study [15], that supported the find‐
ings on 7q, noted additional loci at 2q31-q32, 16p13 and 19p13, that overlapped to some extent
with regions identified in the IMGSAC analyses. Fine mapping of the 2q31-q32 led to addi‐
tional evidence implicating the genes SLC25A12, STK39 and ITGA4 as putative risk genes for
ASD. As with most candidate genes examined in small samples, these associations were vali‐
dated by some [40-42] but not all studies [43-46]. The positional candidature of the 2q31-q32
was further supported by a case study of a young Irish male with high-functioning autism
with a complex translocation traversing chromosome 2q32 (46,XY,t(9;2)(q31.1;q32.2q31.3))
[47]. Fine mapping and mutation analysis identified an association with a polymorphism
within the splice donor sequence of exon 16 of the ITGA4 gene and ASD (rs12690517; P = 0.008)
[48].
In a study of Finnish families, Auranen and colleagues [49, 50], who included individuals with
autism, infantile autism, Asperger syndrome (AS) and developmental dysphasia reported a
significant linkage to 3q25-q27. This was supported by suggestive evidence at 3q25-q27 in a study
of AS also in the Finnish population [51] as well as linkage at 3q25-q27 in a single large extended
Utah pedigree of Northern European ancestry [52].
Interestingly,  the  advent  of  large collaborative  studies  by the  Autism Genome Research
Exchange (AGRE), the Autism Genome Project (AGP) and the National Institute of Men‐
tal  Health (NIMH) has not yielded stronger evidence in favour of  specific  loci.  Liu and
colleagues  using  data  from  110  multiplex  families  from  the  AGRE  collection  [16]  ob‐
served  only  suggestive  linkage  on  chromosomes  5p13,  Xq26-qtel,  and  19q12  alongside
modest support for previously reported linkage on 7q (7q31 and 7q36) and 16p13. A fol‐
low-up analysis  including 235 additional  AGRE multiplex families  was again limited to
only suggestive  loci at chromosomes 17q11, 5p13, 11p11-p13, 4q21-q22 and 8q24 [53]. In a
much larger collection of  1168 multiply-affected families from the AGP (including fami‐
lies previously included in the AGRE, CPEA, IMGSAC, PARIS and Seaver linkage stud‐
ies),  Szatmari and colleagues identified suggestive  linkage to chromosome 11p12-p13 and
a large region on chromosome 15q23-q25 [14].  Of the regions that were featured promi‐
nently in previous linkage analyses, there was only modest support for previously high‐
lighted  linkage  regions  on  chromosome 2q31  (female  autism-probands)  and  7q22  (male
ASD-probands) from families of European ancestry [14].  A similarly large linkage study
of  1031  families,  including 1553  affected offspring,  Weiss  and colleagues  identified  sug‐
gestive  linkage at 6p27 and significant linkage at 20p13 [54].
Early association studies examined whether specific variation in genes was associated with
the disease and focused on candidate loci identified from linkage and cytogenetic studies (po‐
sitional candidate genes) as well as in genes within biological processes that we perceived as
having a role in ASD. In the mid-1990’s Risch and Merikangas [55] demonstrated that where
genetic variants have only small effect on risk the association study is a more powerful ap‐
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proach than linkage to identify genetic risk. However, the transition from candidate gene to
genome-wide association studies was not realised until technological advances firstly enriched
the maps of common variation across the genome and secondly enabled the interrogation of
these variants en masse as part of genome-wide SNP arrays.
Wang and colleagues [56] performed one of the first GWAS on individuals in European an‐
cestry individuals from the AGRE collection, the Autism Case Control Collection and unaf‐
fected controls from the Children’s Hospital of Philadelphia control collection. Neither family-
based nor case-control analysis alone yielded genome-wide significant findings. However, in
a combined analyses the authors identified genome-wide significant association on chromo‐
some 5p14.1 (rs4307059; P =3.4 x 10-8) and a number of additional association signals on chro‐
mosome 13q33.3, 14q21.1 and Xp22.32. The 5p14.1 association was validated in the
Collaborative Autism Project (CAP) and Centre for Autism Research and Treatment (CART)
study. The authors found a modest to strong replication of the association signal on chromo‐
some 5p14.1. In a reciprocal study with the CAP and CART study as the discovery sample
followed by validation using the AGRE dataset was published in parallel by Ma and colleagues
[57]. The authors examined approximately 500k SNPs, more than in the Wang report and albeit
not genome-wide significant, they retained the association signal on chromosome 5p14.1.
A second independent GWAS was reported by Weiss and colleagues [54]. In the initial scan
the authors did not find any GW-significant associations. However, as with the previous
GWAS, additional supplementation of their family-based studies with a case-control set de‐
rived from 90 probands without parental data garnered some additional signal for the top hits.
A replication consortium of greater than 2000 trios was genotyped for 45 SNPs across all of
the top associated regions. The only marker that showed evidence of replication resides on the
short arm of chromosome 5 at 5p15. Although, like Ma and colleagues, this report has consid‐
erable overlap with the AGRE families reported by Wang and colleagues, the authors did not
observe strong association at 5p14.1. The chromosome 5p association lies in close proximity
to TAS2R1. The TAS2R1 gene encodes a G-protein coupled receptor that is involved in bitter
taste recognition. The authors highlight a more biologically plausible ASD candidate gene
approximately 80 Kb telomeric, SEMA5A. SEMA5A encodes a gene important in axonal guid‐
ance and has been shown to be down regulated in the occipital lobe cortex, lymphoblast cell
lines and lymphocytes from individuals with autism.
Two additional GWAS followed by the Autism Genome Project (AGP) [39, 58]. In the first
report of 1369 families, Anney and colleagues identified a single GW-significant finding on
chromosome 20 at position 20p12 within the MACROD2 (MACRO-domain containing 2) gene
locus (rs4141463; P = 2.1 x 10-8; OR = 0.56). Weak statistical support was observed for MAC‐
ROD2 in an AGRE validation sample, albeit showing the same direction of effect for the risk
allele. In a follow-up study using an additional 1301 families the authors showed little if any
signal of association (rs4141463; P = 0.206, OR=0.91). In a combined analyses the association at
MACROD2 was less compelling (rs4141463; P = 1.2 x 10-6; OR=0.77). The role of MACROD2 is
largely unknown although structural variation in this gene and specifically the region har‐
bouring the ASD association signal have been implicated in schizophrenia [59, 60] and epilepsy
[61]. However, this same region has been identified as a hotspot for deletions in the genome
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identified as a region of large rare deletions [62]. MACROD-like proteins are highly conserved
across evolutionary time, which may indicate an essential role. The MACRO-domain is an
ADP-ribose binding module [63] and has been implicated in the ADP-ribosylation of proteins,
an important post-translational modification that occurs in a variety of biological processes
such as DNA repair [64], heterochromatin formation, histone modification and sirtuin biology
[65-67] as well as long-term memory formation [68]. The association signal observed at
rs4141463, albeit tagged to the MACROD2 gene, resides in an intronic region near an intragenic
non-protein-coding-RNA, NCRNA00186 (MACROD2-AS1). Two MACROD2-AS1 transcripts
have been reported of 673bp and 1230bp in length, located on the reverse strand between exon
5 and 6 of MACROD2. Anti-sense RNAs typically interact with mRNA, resulting in transcrip‐
tional or post-transcriptional effects and have been linked to brain development and plasticity
[69]. However, unlike MSNP1AS described for the 5p14.1 association observed by Wang and
colleagues, a function for this non-coding RNA has not yet been reported.
The strongest association signal observed by the AGP combined analyses was rs1718101 (P =
7.8 x 10-9; OR=2.13 (1.63-2.80)), a SNP within the CNTNAP2 gene which was previously impli‐
cated in ASD through linkage analyses. This association was observed in a secondary analysis
which was restricted to ASD individuals of European ancestry with a higher IQ. Anney and
colleagues suggest that with the current data “few if any common variants have an impact on
risk exceeding (an effect size of) 1.2 (or below its inverse).” In an attempt to seek evidence for
or against common variants having an impact on risk, the authors constructed an allele-score.
The allele-score method, as previously described by Purcell and colleagues [70], calculates a
score for each individual based on number of risk associated alleles that the individual pos‐
sesses. This score is then used to either calculate the predictive value of the score between cases
and controls or estimate the amount of variance that this score predicts for the disease. Allele-
scores derived from the transmission of common alleles from the families described in the AGP
stage 1 GWAS [58] could significantly predict case-status in the independent Stage 2 sample.
The authors concluded however that despite the limited findings for individual loci from
GWAS studies to date, en masse the top results exert a detectable impact suggesting that as the
sample sizes increase, additional significant loci will emerge. Putting together samples of the
size seen in successful GWAS studies in other disorders (n>20,000) is challenging for a disorder
with a complex phenotype such as ASD.
4. Structural variation: Chromosomal abnormalities in autism
Autism has been frequently associated with chromosome abnormalities, such as deletions,
duplications, inversions, or translocations; with abnormalities on the long arm of Chromosome
15 and with numerical and structural abnormalities of the sex chromosomes. Reddy in a survey
of chromosomal abnormality in autism found one in 14 of 421 individuals (3.33%) [71]. These
fourteen cases broke down into 4 supernumerary chromosome markers, 4 deletions, 3 inver‐
sions and 3 duplications. Several reviews have since confirmed that such abnormalities can be
identified in ~3-5% of these patients [72, 73]. The regions commonly reported include 2q37,
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5p14, 5p15, multiple locations on chromosome 7, 11q25, 15q11-q13, 16q22.3, 17p11.2, 18q21.1,
18q23, 22q11.2, 22q13.3 and Xp22.2–p22.3.
Many studies have converged on particular chromosomal abnormalities in autism, the most
common of which are maternally inherited duplications at 15q11-13. These duplications are
found in as many as 1–3% of patients diagnosed with autism.
Another relatively common chromosomal variant is the 22q11.2 microdeletion syndrome, or
velocardiofacial syndrome (VCFS) that occurs in ~1/4000 live births. This syndrome is also
identified in the context of learning disability or in schizophrenia and has a complex pheno‐
typic expression affecting multiple organs. The physical features include a typical facial ap‐
pearance, (long face, narrow palpebral fissures, flattened malar eminences, prominent nose
and small mouth); anatomical and/or functional abnormalities of the palatal shelves such as
cleft palate and velopharyngeal insufficiency; lymphoid tissue hypoplasia and heart defects.
A wide range of childhood onset developmental symptoms and disorders are described in
association with the VCFS mutation [74] including attention deficit hyperactivity disorder
(ADHD), oppositional defiant disorder, phobias, anxiety, obsessive compulsive disorder and
autism spectrum disorders.
5. Copy number variation
The human genome has both sequence and structural variation, the majority of which has no
functional consequences and is unrelated to any disorder. Structural variation may be bal‐
anced, such as is the case for inversions and balanced translocations or may alter DNA copy
number. The later, referred to as copy number variants (CNVs) extend from the duplication
or deletion of a single base pair to whole chromosome abnormalities. The term CNV is gen‐
erally used to indicate the larger changes. Initially, large CNVs were identified with classical
chromosomal staining and light microscopy. As many of these abnormalities were initially
identified in sub-telomeric regions, there was interest in knowing if such deletions, duplica‐
tions and other re-arrangements might occur throughout the genome. This hypothesis was
confirmed with the development of high resolution array based comparative genomic hy‐
bridization (aCGH) [75].
In the arrays, comparative hybridization is performed with DNA immobilized on a platform
such as a glass slide. Initially the DNA arrays consisted of human DNA cloned into bacterial
artificial chromosomes (BAC arrays) representing the human genome at approximately 1Mb
intervals. The present arrays consist of 25-base pair oligonucleotides (probes). In the last dec‐
ade the resolution of the arrays have improved to the extent that the number of smaller CNVs
identified in the genome that were previously invisible to microscopy has increased enor‐
mously. Deletions and duplications at least as small as 10kb are now known to occur through‐
out the genome.
Interestingly, some CNVs appear to differ from single nucleotide polymorphisms (SNPs) in
terms of locus specific mutation rates. Rates for genomic re-arrangements range from 10-4 to
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10-5, a rate that is considerably more frequent than point mutations [76]. This high mutation
rate, coupled with reduced fecundity in some carriers, and the fact that comparatively, they
affect a larger proportion of the genome, make CNVs a potentially important source of new
and recent mutation in neurodevelopmental disorders.
6. CNVs in autism
As discussed above, autism is a phenotypic feature of many genomic disorders. Betancur [77],
in her review, lists 103 disease genes and 44 genomic loci where autism or autistic like behaviors
have been described. ASD is diagnosed in ~30% of males with Fragile X syndrome and in
reverse, Fragile X mutations are found in as many as 7–8% of individuals with ASD [78]. Sim‐
ilarly, mutations in MECP2, the Rett Syndrome gene, have been found among cases of autism
that do not have the classical Rett phenotype and autism patients have an increased risk for
neurofibromatosis and other rare monogenic diseases like tuberous sclerosis and Joubert’s
Syndrome, again inversely patients with these disorders have an increased risk for having
autism [79, 80].
The  genes  and  loci  listed  in  the  Betancur  study  are  all  causally  implicated  in  learning
disability  (LD),  indicating  that  these  two neurodevelopmental  disorders  share  some ge‐
netic  risk  factors.  Early  use  of  aCGH  in  non-syndromic  autism  suggested  the  method
had  promise  in  detecting  hitherto  unrecognized  CNVs.  For  example  Jacquemont  et  al
[81]  identified  6  deletions  and 2  duplications  in  29  patients  presenting  with  syndromic
ASD  where  previous  high  resolution  karyotyping  was  reported  as  normal.  Another
study  showing  the  potential  for  CNV  analysis  was  a  large  linkage  study  [14]  using  a
10k  SNP array  where  intensity  data  was  used to  determine  copy number.  The  authors
highlight  some individual  findings  including a  family  with  two sisters  with  ASD,  both
of whom had a ~300kb deletion on Ch. 2p16 that included the coding exons of the neu‐
rexin 1 gene (NRXN1). A second finding was a recurrent 1.1Mb duplication at Ch. 1q2.1
in four affected individuals  from three families,  a  third was a  ~900kb de novo duplica‐
tion at 17p12 in an affected sib-pair, and with the same region appearing as a maternal‐
ly  inherited  deletion  in  two  male  siblings,  with  a  paternally  inherited  deletion  in  a
further  female.  Duplications  in  this  region cause Charcot-Marie-Tooth 1A (CMT1A)  and
hereditary  neuropathy  with  pressure  palsies  when  deleted,  and  overlapping  deletions
are seen in Smith-Magenis syndrome that includes autism symptoms in many cases [82].
A key development was the report of de novo copy number variants in autism [83] using
aCGH. These authors showed that individually rare CNVs, and in particular ones that affect
neurodevelopmental genes, were enriched in cases. They further suggested that the rate of de
novo CNVs differed between simplex cases, where they occurred in 10% of families in the
sample, and familial cases where they occurred in 3% of families, suggesting that sporadic and
familial cases of ASD might have different underlying genetic mechanisms, although not all
studies since then have found this distinction. Several studies of CNVs in large autism case
and family series have followed. Marshall et al. [84] examined 427 ASD families using a 500k
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SNP array and karyotyping by standard clinical diagnostic method. A de novo rate of 7.1%
and 2.0% in simplex and multiplex families respectively was observed, supporting the previ‐
ous findings [83]. Families occasionally showed more than a single de-novo event where both
may combine to produce risk. A further set of loci were identified in two or more unrelated
families, increasing the evidence supporting a pathogenic role. As with the LD literature, at
some loci, both deletions and duplication were found suggesting a more complex mechanism
than simple over or under-expression of gene products. Of the 196 inherited CNVs confirmed
experimentally, 90 were of maternal and 106 of paternal origin. The authors list numerous
potential ASD candidate genes where a structural change was either de-novo, found in two or
more unrelated ASD cases, or, in the case of the X-chromosome, transmitted from an unaffected
mother. Given their rarity, very few individual CNVs in this study provided statistical evi‐
dence to support their role in autism. For example, 4 CNVs from 427 cases were found at the
DPP6 – a subunit that affects the function of Kv4.2 channels at the same site of expression as
SHANK3 and NLGN gene products. Only one similar CNV was found in 1652 controls (Fisch‐
er’s exact test p = 0.016). In keeping with previous cytogenetic findings and the emerging
overlap in disorders involved, CNVs were found in ASD cases that involved known loci or
genes in disorders such as Waardenburg Type IIa, Speech and language disorder, learning
disability and VCFS. A further study [85] found a total of 51 CNVs in 46 cases and not in the
controls. 42 of these were familial and 9 de novo with recurrence in two or more cases at three
loci. In total, case specific CNVs were found in 11.6% of cases, although, in keeping with the
Marshall et al [84] study, none were individually associated with case status with the majority
being observed in only a single case. Pinto et al [86] compared CNVs in 996 ASD cases of
European ancestry to 1,287 matched controls, using the Illumina 1M SNP array. Cases were
found to carry a higher global burden of rare, genic CNVs, especially so for loci previously
implicated in either ASD and/or intellectual disability. Nearly 6% of the cases had de-novo
mutations with some having two or more events. Novel candidate genes were identified that
were de-novo in cases and not controls, including SHANK2, SYNGAP1 and DLGAP2. In keep‐
ing with previous studies only one novel CNV (maternally inherited X-linked deletions at
PTCHD1) occurred statistically more frequently in cases compared to controls (7 vs 0). PTCHD1
involvement in autism and LD was further extended and confirmed in a focused examination
of the PTCHD1 locus in cohorts of autism and LD cases and extending the study of CNVs to
sequence data, identifying additional maternally inherited missense mutations in 8 probands
not seen in controls [87]. In the Pinto et al study[86], certain gene sets were found to be enriched
for case deletions but not duplications. These included sets involved in cell and neuronal de‐
velopment, projection, motility and proliferation; GTPase/Ras signaling known to be involved
in regulating dendrite and spine plasticity; and kinase activity/regulation. There was addi‐
tional overlap with gene sets thought to be involved in LD including microtubule cytoskeleton,
glycosylation and CNS development/adhesion. More recently, Salyakina and colleagues [88]
have shown the value of extended multiply affected families in a CNV study of 42 families.
They found 5 deletions and 7 duplications that co-segregated with ASD, two overlapping with
known autism CNVs on 7p21.3 and 15q24.1 and two near regions on 3p26.3 and 12q24.32
previously associated with schizophrenia.
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As the resolution of the probe arrays improves, smaller CNVs will be detected, and the boun‐
daries of previously identified CNVs will become more refined [89]. Nord et al. [90], examined
genomic DNA of 41 children with autism and 367 healthy controls for rare CNVs using a very
high-resolution aCGH platform. They found that cases were more likely than controls to have
CNVs as small as ~10 kb, likely to affect genes involved in transcription, nervous system de‐
velopment, and receptor activity. They found that expression of CNTNAP2, ZNF214, PRODH
and ARID1B genes affected by CNVs were decreased in probands compared with controls
suggesting reduced expression as a potentially aetiological factor during development.
Larger samples, particularly those based on families, will also enable the improved estimation
of the overall effects of de-novo mutations and the assessment of rare recurrent events as
disease associated mutations [91]. These authors studied 1124 autism families containing pro‐
bands, unaffected parents and an unaffected sibling using the Illumina 1M SNP array. In a
related paper [92] they were able to confirm de novo CNVs identified using the SNP array
with those detected using a Nimblegen 2.1M aCGH platform. A combined total of 58 rare de
novo CNVs were identified across the two studies with each array type identifying 95% of the
total. However, the sensitivity for smaller CNVs was low for both arrays. Overall, the burden
of rare de novo CNVs in the Sanders et al [91] study was greater in probands than in siblings
for total number, size and gene content. Using the rate in siblings as a control to evaluate
findings in the cases, there was strong individual statistical support for recurrent de novo
duplications at 7q11.23, the locus at which deletions cause Williams-Beuren syndrome; dele‐
tions at 16p11.2 and duplications at 16p11.2. In addition the authors observed 8 loci at which
rare transmitted CNVs, present only in probands, overlapped with one of the 51 regions in
probands containing one or more rare de novo CNVs. However, the rare transmitted CNVs
were not more likely to be in cases than in unaffected siblings, even when subdivided into
genic, exonic, brain-expressed or previously identified as ASD related. This suggested that the
excess burden in their sample was due to rare de novo events, although when the gene sets
were applied to gene pathway analysis, more pathways showed enrichment in the case set
compared to the sibling set. To date, the number of definitive replicated findings for ASD from
all studies has been small, with the data suggesting an extreme heterogeneity model with no
single risk variant occurring in more than 1% of cases.
7. Mutation rates and models of risk in autism
Given the replicated finding that de-novo mutations are more frequent in simplex cases com‐
pared to familial cases, Zhao et al [93] have suggested a model of autism risk in which families
fall into two groups; those in which the overall risk for autism is low, representing the majority
of families, and those in which the risk is higher due to a disease mutation with a dominant
mode of transmission with greater penetrance in males compared to females. Under this mod‐
el, sporadic cases of autism occur in low-risk families due to a de novo mutation of relatively
high penetrance, whereas familial autism occurs due to the inheritance of an existing mutation
from a clinically unaffected or asymptomatic parent. In another model, Girirajan et al. [94]
proposed the necessity in some families for a second mutation to lead to severe neurodeve‐
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lopmental disorder. In this study, individuals with childhood developmental delay are en‐
riched approximately fourfold for a rare 520-kb 16p12 deletion. In nearly all cases examined
(22/23), the deletion was inherited. Thus, 16p12 deletions appear to be an example of inherited
predisposition to neurodevelopmental disorder with dominant transmission. However, these
individuals were more likely to carry a second large (>500 kb) CNV compared to matched
controls, and clinical features of those with a second large CNV were typically more severe
than those with the 16p12 deletion alone. Itsara et al. [95] suggest that multiply affected autism
pedigrees segregate an existing inherited mutation of low penetrance which by itself is rarely
sufficient to cause disease. Secondary mutations, such as de-novo mutations are required to
manifest as disorder. Whether or not these second hits are disease specific remains to be ex‐
amined. The authors propose that the excess of de novo CNVs among cases may be due to a
depletion of second-hits in the unaffected sibling due to the initial low penetrant mutation
segregating in the family. The abundance of inherited low penetrance mutations and the high
rate of de novo CNVs in the population enable multiple cases to appear within families with
apparently unusual patterns of inheritance.
8. Next-generation sequencing studies
There is an increasing literature describing the occurrence of single nucleotide mutation in
ASD. Unlike the common polymorphisms described earlier, these variants are often rare or
private to an individual and considered to have a large impact on the gene's function. Early
studies have focused on candidate genes with strong a priori evidence to suggest causation,
such as the Neuroligin and Shank encoding genes. Sanger sequencing of the exons of families
with ASD have identified many putatively causative mutation in these synaptic proteins [96,
97]. As with the transition from candidate gene association studies to GWAS, the advent of
more sophisticated high-throughput next-generation sequencing approaches have enabled
many genes to be screened in a single experiment. This has extended to the systematic scanning
of the whole exome of individuals with ASD to identify putative risk mutations.
In April 2012, three key manuscripts were published in Nature describing a considerable
exome sequencing effort of 622 family trios and 250 unaffected siblings [98-100]. In these stud‐
ies the focus was on de novo mutation in the exome of individuals with ASD. De novo mutations
are those changes that occurred in the child which are not inherited from the parent. Given
the natural mutation rate, the number of families studied and the number of genes under
investigation it was estimated that three independent mutations would provide strong evi‐
dence implicating a gene in ASD, whilst two independent mutations would be suggestive but
not definitive. Unfortunately in these studies no gene was burdened with three independent
mutations, whilst several revealed two independent de novo mutations. Follow-up analyses
across the studies of the two-hit genes in a cohort of over 2600 individuals with ASD and over
1600 typically developing controls identified additional non-synonymous mutations in KAT‐
NAL2 (katanin p60 subunit A-like 2), CHD8 (Chromodomain-helicase-DNA-binding protein
8), GRIN2B (Glutamate [NMDA] receptor subunit epsilon-2), LAMC3 (Laminin subunit gam‐
ma-3), SCN1A (sodium channel, voltage-gated, type I, alpha subunit) and SCN2A (sodium
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channel, voltage-gated, type II, alpha subunit). Despite the early caution regarding the number
of de novo events observed per gene, the burgeoning evidence from focused re-sequencing of
these suggests that other families with ASD have damaging loss-of-function mutation in these
genes.
9. Implications of genomic studies for clinical practice
Genetic findings to date in autism include known genetic syndromes such as Rett and Fragile
X; chromosomal structural variation such as duplications on ch15 and deletions on ch22 and
increasing numbers of CNVs, many de novo, in a small proportion of cases, especially those
with co-morbid developmental abnormalities. Common variants are only slowly emerging
from genome-wide studies but sample sizes are still relatively modest compared to other dis‐
orders. The diagnosis remains as a clinical one, but genetic testing has diagnostic, prognostic
and family planning implications, and in the coming years may also be of importance with
respect to potential treatments for specific conditions such as Rett and Fragile X. Therefore, a
clinical genetics evaluation should be considered in ASD children in order to identify syn‐
dromic forms of autism, identify familial cases, and drive diagnostic testing. Genetic testing
using aCGH has been recommended by the American Academy of Pediatrics [101] and the
American College of Medical Genetics [102, 103], particularly to evaluate aetiological hetero‐
geneity and identify syndromes. For the vast majority of cases with an identified genetic cause,
there is no specific benefit in terms of treatment, but the diagnosis itself may be of value to
parents seeking an explanation for the symptoms they see in their child. Acceptance of the
disorder may be easier in the presence of a known cause as echoes of social causation and
blame can still be heard. Family investigation may also be warranted, particularly where the
proband has an identified genetic causation as recurrence risk in siblings may have implica‐
tions for family planning. If a genetic cause of pathogenic significance is identified, the recur‐
rence risk for sibs may be established according to the particular genetic diagnosis. In the
majority of cases, no genetic alteration is found, and an empirical risk for siblings of 10-20%
can be provided. Establishing a clear de novo origin for a given mutation may enable a low
risk estimate in siblings although there are caveats relating to the exact origin of the mutation.
Finally, and re-stating the main goal of genetic research in ASD, a better understanding of
underlying biology may lead to novel and unexpected treatment possibilities. Early signs of
this are emerging in human trials for treatments aimed at the specific mutations found in Rett
and Fragile X syndromes.
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